Sign in
CompletedPhase 4

A randomized trial investigating the superiority of TDM-optimized teicoplanin dosing versus standard of care

Key facts

Who runs it
Stichting Radboud University Medical Center
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 4
People taking part
74 people enrolled
Started
17 Aug 2023
Ended
20 Feb 2026
Type of study
Interventional
Record updated
1 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • The patient is admitted to the Radboudumc
  • The patient is at least 18 years old on the day of inclusion
  • The patient is treated with teicoplanin as part of standard care
  • The patient or a representative is willing to sign the Informed Consent Form

Who cannot take part

  • The patient has previously participated in this study
  • Expected duration of teicoplanin therapy is less than 5 days
  • The patient receives any form of RRT other than CVVHD / CVVHDF
  • Pregnant individuals

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate target attainment at 5 days after treatment initiation in patients receiving TDM- guided dosing versus patients receiving standard dosing.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
1 July 2025